<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Evidence for Inquiry by House of Commons Science and Technology Committee into blood, tissue and organ screening following vCJD fears</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:center"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">Written evidence submitted by Professor Sheila M Bird (BTO0011) </span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 10pt 49.51pt; padding-left:4.49pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">BACKGROUND and REASONS for SUBMITTING EVIDENCE</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">1.1 I am a biostatistician programme-leader at the Medical Research Council’s (MRC) Biostatistics Unit and hold a visiting professorship in the Department of Mathematics and Statistics at Strathclyde University in Glasgow. My </span><span style="font-family:Calibri; font-size:11pt">biostatistical</span><span style="font-family:Calibri; font-size:11pt"> work on Transmissible Spongiform </span><span style="font-family:Calibri; font-size:11pt">Encephalopathies</span><span style="font-family:Calibri; font-size:11pt"> (TSEs) </span><span style="font-family:Calibri; font-size:11pt">and on organ donation and transplantation </span><span style="font-family:Calibri; font-size:11pt">spans two decades. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">I gave evidence to the BSE Inquiry, quantified UK BSE dietary exposure by birth-cohort</span><span style="font-family:Calibri; font-size:11pt"> and gender</span><span style="font-family:Calibri; font-size:11pt">, and have been instrumental in European TSE surveillance designs.</span><span style="font-family:Calibri; font-size:11pt">  A</span><span style="font-family:Calibri; font-size:11pt">s a biostatistician</span><span style="font-family:Calibri; font-size:11pt">, I have needed to be deeply immersed</span><span style="font-family:Calibri; font-size:11pt"> in, and </span><span style="font-family:Calibri; font-size:11pt">am admiring of</span><span style="font-family:Calibri; font-size:11pt">, TSE science.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">I conducted the 1988-90 confidential audit of all deaths in intensive care units in England and Wales by which relatives’ refusal-rate (then 30%) was quantified and the barriers to organ-specific donation from brain-stem dead potential donors were identified. I have never been a supporter of the NHS Organ Donor Register as opt-out registrations would be many fewer and the associated registration and analyses more manageable. In response to the 2008 report by the Organ Donor Taskforce, Bird and Harris (2010) estimated the plausible gain from presumed consent.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:11pt">1.2 In 1988, I joined the MRC’s Working Party on Human Spongif</span><span style="font-family:Calibri; font-size:11pt">orm </span><span style="font-family:Calibri; font-size:11pt">Encephalopathies</span><a name="_GoBack"></a><span style="font-family:Calibri; font-size:11pt">. During the next 20 years, I served on a range of sub-committees which dealt with TSEs: in the UK, for MRC, Department of Health (DH), Spongiform Encephalopathy Advisory Committee (SEAC), Health Protection Agency (HPA, now Health Protection England, HPE); in Europe, under the auspices of the Ad Hoc TSE/BSE Subgroup of the European Commission Scientific Steering Committee (1999-2003). In particular, I designed Europe’s late-stage BSE/TSE surveillance in cattle and sheep at abattoirs (which revolutionized understanding of </span><span style="font-family:Calibri; font-size:11pt">scrapie</span><span style="font-family:Calibri; font-size:11pt"> epidemiology) and so was </span><span style="font-family:Calibri; font-size:11pt">rapporteur</span><span style="font-family:Calibri; font-size:11pt"> on </span><span style="font-family:'Times New Roman'; font-size:10pt; font-style:italic">Requirements for statistically authoritative BSE-TSE surveys.</span><span style="font-family:'Times New Roman'; font-size:10pt">  European Commission, Brussels: November 2001.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">1.3 My research on human TSEs has been funded by the Medical Research Council mainly (and Food Standards Agency) and has focused on two aspects: first, quantification of UK’s dietary BSE exposure by gender and birth-cohort; secondly, the need to increase substantially the extent of human surveillance - by gender, birth-cohort and genotype at </span><span style="font-family:Calibri; font-size:11pt">codon</span><span style="font-family:Calibri; font-size:11pt"> 129 of the </span><span style="font-family:Calibri; font-size:11pt">prion</span><span style="font-family:Calibri; font-size:11pt"> protein - for sub-clinical carriage of </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt"> (more specifically: presence of abnormal </span><span style="font-family:Calibri; font-size:11pt">prion</span><span style="font-family:Calibri; font-size:11pt"> protein, </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt">). </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">1.4 Cooper and Bird (2003) showed that UK dietary BSE exposure had been greater in the 1940-69 birth-cohort than in those born in 1970-95 and that dietary BSE exposure therefore did not explain the young age of </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt"> cases unless susceptibility to clinical progression from dietary BSE exposure was strongly age-dependent, for example markedly decreased beyond teenage.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">1.5 In committees and publications, I proposed </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> surveillance at forensic autopsies, for which an HPA protocol was developed and ethically-approved; but did not proceed. Instead, HPA re-grouped and successfully oversaw </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> surveillance by gender and birth-cohort (and with genotyping of </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> positives) in 30,000 appendices, results of which were recently published in British Medical Journal. Continuation from 30,000 to at least 100,000 tested appendices was originally envisaged.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">1.6 More controversially, I have also argued that those caught up in </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-at-risk networks who have a guesstimated </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-risk of at least 1% should </span><span style="font-family:Calibri; font-size:11pt; font-style:italic">either</span><span style="font-family:Calibri; font-size:11pt"> be subject of mandatory forensic post-mortem in the interest of public health </span><span style="font-family:Calibri; font-size:11pt; font-style:italic">or at the very least</span><span style="font-family:Calibri; font-size:11pt"> be asked to give permission-in-life for </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-informative tests to be done post-mortem in the event of their death and consent-rate monitored. Neither is done.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">1.7 UK’s </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> surveillance in appendices suggests that around 1 in 2,000 tests positive.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">1.8 </span><span style="font-family:Calibri; font-size:11pt"> If similar surveillance - at autopsy, on </span><span style="font-family:Calibri; font-size:11pt">anonymised</span><span style="font-family:Calibri; font-size:11pt"> appendix tissue, or by use of a suitable blood or urine test in </span><span style="font-family:Calibri; font-size:11pt">anonymised</span><span style="font-family:Calibri; font-size:11pt"> blood samples from at-risk persons - were applied to those caught up in </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-at-risk networks, then we might expect 1 in 100 to be positive for </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> if the 1% assumption were sound.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">1.9 If the 1% expectation proved unsound</span><span style="font-family:Calibri; font-size:11pt">, </span><span style="font-family:Calibri; font-size:11pt">then the assumptions underlying its</span><span style="font-family:Calibri; font-size:11pt"> derivation need revision. But, without empirical evidence from surveillance in those highly-at-risk, there can be no revision. </span><span style="font-family:Calibri; font-size:11pt">W</span><span style="font-family:Calibri; font-size:11pt">e bury and cremate valuable evidence</span><span style="font-family:Calibri; font-size:11pt"> on subclinical carriage of </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">.</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 10pt 49.51pt; padding-left:4.49pt; text-align:center; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">BLOOD, TISSUE &amp; ORGAN SCREENING following </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">vCJD</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">SUMMARY</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Investment in the formal assessment of prototype blood/urine tests for </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super"> </span><span style="font-family:Calibri; font-size:11pt">is a key, deliverable research and surveillance priority (please see notes 2-4; 6-8; 24-26). </span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">UK’s </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> surveillance in appendix tissues should continue at least until 50,000 male appendices have been tested and  50,000 female appendices; and until 50,000 appendices have been tested in the 1941-65 birth-cohort because higher </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super"> </span><span style="font-family:Calibri; font-size:11pt">prevalence is predicted in males and in the older birth-cohort by UK’s BSE dietary consumption (please see notes: 18-23).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Blood and other samples are being collected from persons in the UK who are “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk</span><span style="font-family:Calibri; font-size:11pt">”:  in anticipation of their use in test-validation </span><span style="font-family:Calibri; font-size:11pt; font-style:italic">or</span><span style="font-family:Calibri; font-size:11pt"> for surveillance purposes</span><span style="font-family:Calibri; font-size:11pt"> when a suitable test becomes available (please see notes: 8-10).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">UK’s number </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">“at-</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">vCJD</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">-high-risk”</span><span style="font-family:Calibri; font-size:11pt"> (that is: approximated as 1% or higher </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-risk) is at least 5,000 and probably nearer 10,000. </span><span style="font-family:Calibri; font-size:11pt">UK needs to</span><span style="font-family:Calibri; font-size:11pt"> monitor their age-related mortality and hospitalizations. We also need regular updates on the numbers of “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk” persons who have provided blood or other biological samples for use in </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-related research or surveillance (please see notes: 9-11).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Attention should focus on how many of those</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> “at-</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">vCJD</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">-high-risk” </span><span style="font-family:Calibri; font-size:11pt">have </span><span style="font-family:Calibri; font-size:11pt">died without being subject to post-mortem or </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-informative testing. There may be a case for mandatory autopsy in the public interest (please see notes: 12-17).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super"> </span><span style="font-family:Calibri; font-size:11pt">surveillance in those</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> “at-</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">vCJD</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">-high-risk” </span><span style="font-family:Calibri; font-size:11pt">is necessary to enable to revision or refinement of their </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk status (please see notes: 13-14).</span></li></ul><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><br style="page-break-before:always; clear:both" /></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">WRITTEN EVIDENCE</span><span style="font-family:Calibri; font-size:11pt"> on </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">TOPIC 2</span><span style="font-family:Calibri; font-size:11pt"> (is Government and its scientific advisory structure sufficiently responsive re </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-risks) &amp; </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">TOPIC 3</span><span style="font-family:Calibri; font-size:11pt"> (has ongoing blood-related transmission of </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt"> been adequately mitigated)</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.35pt; padding-left:4.65pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">At an oral evidence session on 27</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:Calibri; font-size:11pt"> November 2013, Professors </span><span style="font-family:Calibri; font-size:11pt">Collinge</span><span style="font-family:Calibri; font-size:11pt"> and </span><span style="font-family:Calibri; font-size:11pt">Ironside</span><span style="font-family:Calibri; font-size:11pt"> stressed to the Science and Technology Committee how fundamentally important it is that prototype tests in blood or urine for the detection of abnormal </span><span style="font-family:Calibri; font-size:11pt">prion</span><span style="font-family:Calibri; font-size:11pt"> protein (</span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt">) be further assessed.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.35pt; padding-left:4.65pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt"> Initially, further assessment requires funding for the test/tests to be applied, for example over the course of 3 years, ideally to 25,000-50,000 </span><span style="font-family:Calibri; font-size:11pt">anonymized</span><span style="font-family:Calibri; font-size:11pt"> samples from each of:         </span><span style="font-family:Calibri; font-size:11pt">i</span><span style="font-family:Calibri; font-size:11pt">) UK’s BSE-exposed population, notably </span><span style="font-family:Calibri; font-size:11pt">Biobank</span><span style="font-family:Calibri; font-size:11pt"> participants or UK blood donors born prior to 1986; ii) UK’s minimally BSE-exposed population, such as UK blood donors born after 1990; and iii) a non-UK, minimally BSE-exposed, population which is broadly age-matched to </span><span style="font-family:Calibri; font-size:11pt">i</span><span style="font-family:Calibri; font-size:11pt">), such as USA blood donors born prior to 1986. </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">I endorse this as a </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">key and deliverable </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">research priority.</span><span style="font-family:Calibri; font-size:11pt"> </span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.35pt; padding-left:4.65pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Even if an individual prototype blood test were to be capable of detecting only two-thirds (say) of the </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> –positives that would be expected from testing hitherto in appendix tissues, then instead of observing 25 </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt">-positives in 50,000 samples from group </span><span style="font-family:Calibri; font-size:11pt">i</span><span style="font-family:Calibri; font-size:11pt">), we might find only 16. The test’s false positive rate would, of course, need to be taken into account, and should be estimable from samples of type iii). To date, I believe that Professor </span><span style="font-family:Calibri; font-size:11pt">Collinge’s</span><span style="font-family:Calibri; font-size:11pt"> blood test has recorded zero positives in 5,000 samples of type iii). These preliminary data are sufficient only to be 99% confident that the true </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt">-positive rate in population iii) is less than 1 in 1,000. Clearly, many more samples of type iii) need to be tested for there to be convincing evidence that the false-positive rate is less than, say, 1 in 10,000. </span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.35pt; padding-left:4.65pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Were funding provided to allow the number of control samples tested  to be raised to 50,000 tested samples (rather than 5,000) from population iii), and if the number of </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt">-positives remained at or near zero, then we could be 99% confident that the test’s false -positive rate was less than 1 in 10,000. For surveillance purposes, this would be highly satisfactory because we’d need to “discount” only about three out of 19 positives {where 19 = 16 true positives +3 expected false positives}  in group </span><span style="font-family:Calibri; font-size:11pt">i</span><span style="font-family:Calibri; font-size:11pt">) as potential “false positives”. </span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.35pt; padding-left:4.65pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">For attributable testing</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">, for example of blood donors</span><span style="font-family:Calibri; font-size:11pt">, better performance might be required than around 3/19 positives in group </span><span style="font-family:Calibri; font-size:11pt">i</span><span style="font-family:Calibri; font-size:11pt">) being expected to be “false positives”. The reason is that the false and true positives alike would have to be designated as  “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk” and hence expected to take life-long precautions to protect others from inadvertent surgical transmission.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.35pt; padding-left:4.65pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">However, as Professors </span><span style="font-family:Calibri; font-size:11pt">Collinge</span><span style="font-family:Calibri; font-size:11pt"> and </span><span style="font-family:Calibri; font-size:11pt">Ironside</span><span style="font-family:Calibri; font-size:11pt"> pointed out, prototype-test-performance can often be improved either by dual-testing or by refinement of a prototype-test. However, such </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">later developments will not be invested in, and made, unless</span><span style="font-family:Calibri; font-size:11pt"> prototype tests have demonstrated an acceptable performance</span><span style="font-family:Calibri; font-size:11pt">, such as for surveillance purposes.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.35pt; padding-left:4.65pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">There are other examples of blood-borne-virus tests being used</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">for surveillance purposes that are inferior to those used for diagnosis.</span><span style="font-family:Calibri; font-size:11pt"> For example, the WASH surveillance studies that my late husband Dr A. Graham Bird and I introduced in the 1990s to quantify the prevalence of HIV and Hepatitis C virus in UK prisoners made use of saliva samples to test for HIV antibodies or for HCV carriage. However, diagnostic testing for HIV/HCV uses blood </span><span style="font-family:Calibri; font-size:11pt">samples. [WASH/C = Willing Anonymous Salivary HIV/Hepatitis C]. The HCV carriage rate in prisoners who had never injected was credibly low at 3% (27/899, 95% CI: 2% to 4%) versus 49% in those who reported injection drug use (265/536, 95% CI: 45% to 54%).</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.35pt; padding-left:4.65pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Blood and other samples are being/have been collected from persons in the UK who are “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk”:  </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">in anticipation of their use in test-validation </span><span style="font-family:Calibri; font-size:11pt; font-style:italic; font-weight:bold">or</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> for surveillance purposes</span><span style="font-family:Calibri; font-size:11pt"> when a suitable test becomes available (see also anticipation by Gore, Bird et al. (1999) re salivary HCV test). </span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.35pt; padding-left:4.65pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">In response to my letter of inquiries on 24</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:Calibri; font-size:11pt"> November 2006 about Epidemiological Reporting by CJD Incidents Panel, the reply by David </span><span style="font-family:Calibri; font-size:11pt">Pryer</span><span style="font-family:Calibri; font-size:11pt">, then-chairman, included a relevant summary table on ‘At-risk’ groups at 1 January 2007, which I expect that the CJD Incidents Panel has regularly updated. </span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">UK’s number “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk” (that is: approximated 1% or higher </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-risk) is at least 5,000 and probably nearer 10,000. Those “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk”  include:  </span><span style="font-family:Calibri; font-size:11pt">i</span><span style="font-family:Calibri; font-size:11pt">) blood component recipients, ii) blood donors to </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt"> cases, iii) recipients of blood donated by donors to </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt"> cases, iv) patients with bleeding disorders treated with UK sourced plasma products, v) non bleeding disorder plasma product recipients, vi) patients exposed through surgery, and vii) highly transfused patients. Groups iv) and vii) {in thousands} together with vi) and ii) {in hundreds} were, and probably still are, the largest.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">UK needs to keep under regular review</span><span style="font-family:Calibri; font-size:11pt"> – at least annually – the mortality and hospitalizations of those “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk” who, like the rest of us, are ageing! We also need regularly to review the numbers of “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk” persons who have provided blood or other biological samples for use in </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-related research or surveillance.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Pending a suitable blood/other test, unless those “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk” have given permission-in-life for </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-informative tests to be done at post-mortem, we are burying or cremating critical evidence about subclinical carriage of </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">. This empirical evidence constitutes the only means we currently have by which to revise the approximation that those whom UK has declared to be “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk” indeed have (or have not) at least a 1% subclinical </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt"> carriage-rate. </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">But how many/few of those “at-</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">vCJD</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">-high-risk” who have since died have actually been subject to post-mortem?</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">No </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt">-positive out of  500 autopsies in “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk” persons would give 99% confidence that their </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-risk had been over-estimated at 1%. Fifty positives in 500 (10%) would certainly mandate much closer attention to the number of operative procedures annually that “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk” persons undergo.  </span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Group iv) survivors have potentially been exposed to Hepatitis C virus (HCV) as well as to </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt"> and, as HCV-carriers age, they may experience HCV-related late liver </span><span style="font-family:Calibri; font-size:11pt">sequelae</span><span style="font-family:Calibri; font-size:11pt">, some of which require surgical management (including transplantation).</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Since the disbanding of UK’s Spongiform Encephalopathy Advisory Committee (SEAC) and its Epidemiology Subcommittee, it is not clear to me how or by whom the matters set out in notes 9 to 14 are kept under review and reacted to, for example by making a case for enhanced surveillance. Epidemiology and surveillance are not strictly the remit of CJD Incidents Panel.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Controversially, I have advocated that, in the public interest, those “at-</span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-high-risk” should be subject to mandatory post-mortem to enable without-consent </span><span style="font-family:Calibri; font-size:11pt">vCJD</span><span style="font-family:Calibri; font-size:11pt">-informative testing in relevant tissues – including appendix and spleen.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">Forensic post-mortem is not unusual, there being some 100,000 per annum in UK.</span><span style="font-family:Calibri; font-size:11pt"> Forensic post-mortem is required in all cases of death in prison custody, or if a death is drug-related or by suicide. The fact that one in five of all deaths at ages 5-44 years in England and Wales is not registered for at least six months is because there has been a coroner’s inquest and, bizarrely, registration of fact-of-death is delayed in England and Wales until cause-of-death has been determined. </span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Lacking SEAC, the surveillance-task in appendix tissues that Health Protection Agency (now Health Protection England, HPE) embarked upon so successfully may not progress to its next critical phase. Surveillance results on over 30,000 appendices were recently reported in the British Medical Journal by Professor Gill and colleagues.  Moreover, the supplement to Gill et al. (2013) summarized that UK has tested just over 43 500 </span><span style="font-family:Calibri; font-size:11pt">anonymised</span><span style="font-family:Calibri; font-size:11pt"> appendix samples for </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt">, of which 19 were positive: roughly 1 in 2,000.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">The task is incomplete until</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">UK has tested at least</span><span style="font-family:Calibri; font-size:11pt"> 50,000 male appendices and at least 50,000 female appendices for presence of </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt">; and at least 50,000 appendices have been tested from the 1961-85 birth-cohort and 50,000 also from the 1941-60 birth-cohort. The design-intention for </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> surveillance in appendix tissue was to determine if </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super"> </span><span style="font-family:Calibri; font-size:11pt">prevalence was different by age-group, gender and genotype. Ideally, we’d test 100,000 in each gender and birth-cohort but this may be infeasible without a high-throughput blood/urine test.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Cooper and Bird</span><span style="font-family:Calibri; font-size:11pt">’s analysis of</span><span style="font-family:Calibri; font-size:11pt"> UK’s BSE dietary consumption</span><span style="font-family:Calibri; font-size:11pt"> by gender and birth-cohort found that median BSE consumption in 1980-96 by males was 37% higher than by females; and was 30% higher by the 1940-69 birth-cohort than by those born in 1970-96.</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> The prior presumption for </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">PrP</span><span style="font-family:Calibri; font-size:7.33pt; font-weight:bold; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> prevalence in UK appendix tissue was therefore higher prevalence for males; and for the older birth-cohort. </span><span style="font-family:Calibri; font-size:11pt">NB: D</span><span style="font-family:Calibri; font-size:11pt">ifferently defined birth-cohorts between </span><span style="font-family:Calibri; font-size:11pt">studies by Gill et al and Cooper and Bird</span><span style="font-family:Calibri; font-size:11pt">.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">UK’s prevalence results in appendix tissue are broadly consistent with the above dietary-BSE priors </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">but with such wide confidence intervals that</span><span style="font-family:Calibri; font-size:11pt"> the results are also consistent with the assumption that </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> prevalence is common between genders and across birth-cohorts (1940-85)</span><span style="font-family:Calibri; font-size:11pt">.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Rightly, the finding of three </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt">-positives in around 10,000 appendix samples in the 1961-85 birth-cohort prompted further testing  - both in that birth-cohort and in the 1941-60 birth-cohort. By the same token, the finding of six </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt">-positives in around 9,000 appendix samples in the 1941-60 birth-cohort should prompt further testing to narrow substantially the uncertainty (currently, 220 to 1450 </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> positives  per million).  Please see </span><span style="font-family:Calibri; font-size:11pt; font-style:italic">Memorandum</span><span style="font-family:Calibri; font-size:11pt">.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">UK propagated BSE. UK thus needs to understand, as well as to mitigate, the public health implications of BSE. If </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> prevalence is indeed higher in older male blood donors, I might prefer my donor to be a younger female (mitigation). If higher, alertness to a different clinical or pathological manifestation of </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> in the ageing 1941-60 birth-cohort is required (surveillance and understanding the science).  If </span><span style="font-family:Calibri; font-size:11pt">PrP</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt"> prevalence is not higher in males and in the older birth-cohort, why not – given the UK’s pattern of dietary BSE consumption? (again, understanding  the science – by questions raised).</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">Fewer than 100,000 appendices have</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">, as yet,</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> been </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">PrP</span><span style="font-family:Calibri; font-size:7.33pt; font-weight:bold; vertical-align:super">SC</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">-tested in UK for surveillance purposes</span><span style="font-family:Calibri; font-size:11pt">: 19 positives identified in around 43 500 samples.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">By contrast, European surveillance for late-stage TSEs in sheep advised that each member-state should aim, annually, to test 100,000 representatively sampled adult sheep slaughtered at abattoirs; and should aim to continue annual surveillance until 100 TSE-positives had been identified.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">If we had a suitable blood test, then high-throughput blood-based surveillance would be simpler than tissue-based. However, I suggest UK should not delay bringing its appendix surveillance up to at least 100,000 tested tissues. Rather, an attempt should be made to associate a blood sample with each appendix sample so that, in time, blood-based surveillance could be conducted on samples from around 60 000 persons who had contributed to completion of  UK’s surveillance of appendix tissues.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">REFERENCES</span><span style="font-family:Calibri; font-size:11pt"> on </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">TOPICS 2 </span><span style="font-family:Calibri; font-size:11pt">&amp;</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> 3</span></p><p style="line-height:13pt; margin:0pt"><span style="font-family:Calibri; font-size:10pt">Gill ON, Spencer Y, Richard-Loendt A, Kelly C, Dabaghian R, Boyes L, Linehan J, Simmons M, Webb P, Bellerby P, Andrews N, Hilton DA, Ironside JW, Beck J, Poulter M, Mead S, Brandner S. Prevalent abnormal prion protein in human appendixes after bovnie spongiform encephalopathy epizootic: large scale survey.</span><span style="font-family:Calibri; font-size:10pt"> BMJ</span><span style="font-family:Calibri; font-size:10pt"> 2013; 347: f5675.</span></p><p style="line-height:13pt; margin:0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt 28.05pt; text-indent:-28.05pt"><span style="font-family:Calibri; font-size:10pt">GORE, SM.  More than happenstance:  Creutzfeldt-Jakob disease in farmers and young adults. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">British Medical Journal </span><span style="font-family:Calibri; font-size:10pt">1995; </span><span style="font-family:Calibri; font-size:10pt; font-weight:bold">311</span><span style="font-family:Calibri; font-size:10pt">: 1416-1418.</span></p><p style="line-height:12pt; margin:0pt 0pt 10pt 28.05pt; text-align:justify; text-indent:-28.05pt"><span style="font-family:Calibri; font-size:10pt">GORE  SM. Bovine </span><span style="font-family:Calibri; font-size:10pt">Creutzfeld-Jakob</span><span style="font-family:Calibri; font-size:10pt"> disease? Failures of epidemiology need to be remedied. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">British Medical Journal</span><span style="font-family:Calibri; font-size:10pt"> 1996; </span><span style="font-family:Calibri; font-size:10pt; font-weight:bold">312</span><span style="font-family:Calibri; font-size:10pt">: 791-793.</span></p><p style="line-height:12pt; margin:0pt 0pt 10pt 28.05pt; text-align:justify; text-indent:-28.05pt"><span style="font-family:Calibri; font-size:10pt">GORE SM. Commentary: age related exposure of patients to the agent of BSE should not be downplayed. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">British Medical Journal</span><span style="font-family:Calibri; font-size:10pt"> 1997; </span><span style="font-family:Calibri; font-size:10pt; font-weight:bold">315</span><span style="font-family:Calibri; font-size:10pt">: 395 - 396. </span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">GORE SM, BIRD AG, CAMERON SO, HUTCHINSON SJ, BURNS SM, GOLDBERG DJ.  Prevalence of Hepatitis C carriage in Scottish prisons: Willing Anonymous Salivary Hepatitis C surveillance linked to self-reported risks. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Quarterly Journal of Medicine 1999;</span><span style="font-family:Calibri; font-size:10pt; font-weight:bold"> 92:</span><span style="font-family:Calibri; font-size:10pt"> 25 - 32.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">EU Scientific Steering Committee [</span><span style="font-family:Calibri; font-size:10pt">rapporteurs</span><span style="font-family:Calibri; font-size:10pt">: BIRD SM and </span><span style="font-family:Calibri; font-size:10pt">Wilesmith</span><span style="font-family:Calibri; font-size:10pt"> JW]. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Report and Opinion: Monitoring some important aspects of the evolution of the epidemic of BSE in Great Britain. Update providing an epidemio</span><span style="font-family:Calibri; font-size:10pt; font-style:italic">&#xad;</span><span style="font-family:Calibri; font-size:10pt; font-style:italic">logical commentary on BSE projections for Great Britain (GB) and on surveillance, as well as on the occurrence of "Born After the Real Ban - BARB" cases. </span><span style="font-family:Calibri; font-size:10pt">European Commission: December 2000.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">EU Scientific Steering Committee Opinion [</span><span style="font-family:Calibri; font-size:10pt">rapporteur</span><span style="font-family:Calibri; font-size:10pt">: BIRD SM]. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Requirements for statistically authoritative BSE-TSE surveys.</span><span style="font-family:Calibri; font-size:10pt">  European Commission, Brussels: November 2001.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">COOPER JD, BIRD SM. UK dietary exposure to BSE in beef mechanically recovered meat: by birth cohort and gender. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Journal of Cancer Epidemiology and Prevention/Journal of Epidemiology and Biostatistics </span><span style="font-family:Calibri; font-size:10pt">2002; 7: 59 - 70.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">COOPER JD, BIRD SM. UK dietary exposure to BSE in head meat: by birth cohort and gender. .</span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Journal of Cancer Epidemiology and Prevention/Journal of Epidemiology and Biostatistics </span><span style="font-family:Calibri; font-size:10pt">2002; 7: 71 - 83.</span></p><p style="line-height:13pt; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">BIRD SM. European Union’s rapid TSE testing in adult cattle and sheep: implementation and results in 2001 and 2002. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Statistical Methods in Medical Research </span><span style="font-family:Calibri; font-size:10pt">2003; 12: 261 - 278.</span></p><p style="line-height:13pt; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">Cooper JD, BIRD SM. Predicting incidence of </span><span style="font-family:Calibri; font-size:10pt">vCJD</span><span style="font-family:Calibri; font-size:10pt"> from UK dietary exposure for the 1940-69 and post-1969 birth cohorts.  </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">International Journal of Epidemiology </span><span style="font-family:Calibri; font-size:10pt">2003; 32: 784 - 791.</span></p><p style="line-height:13pt; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">BIRD SM. Recipients of blood or blood products “at </span><span style="font-family:Calibri; font-size:10pt">vCJD</span><span style="font-family:Calibri; font-size:10pt"> risk”. We need to define their rights and responsibilities and those of others (Editorial). </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">British Medical Journal </span><span style="font-family:Calibri; font-size:10pt">2004; 328: 118 – 119.</span></p><p style="line-height:13pt; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">BIRD SM. Attributable testing for abnormal </span><span style="font-family:Calibri; font-size:10pt">prion</span><span style="font-family:Calibri; font-size:10pt"> protein, database linkage, and blood-borne </span><span style="font-family:Calibri; font-size:10pt">vCJD</span><span style="font-family:Calibri; font-size:10pt"> risks. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Lancet 2004; 364: 1362 - 1364.</span></p><p style="line-height:13pt; margin:0pt"><span style="font-family:Calibri; font-size:10pt">Spongiform Encephalopathy Advisory Committee. </span><span style="font-family:Calibri; font-size:10pt">SEAC epidemiology subgroup </span><span style="font-family:Calibri; font-size:10pt">(SMB member) </span><span style="font-family:Calibri; font-size:10pt">position statement on the vCJD epidemic</span><span style="font-family:Calibri; font-size:10pt">. See </span><a href="http://www.seac.gov.uk/statements/state260106subgroup.htm"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://www.seac.gov.uk/statements/state260106subgroup.htm</span></a></p><p style="line-height:13pt; margin:0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="line-height:13pt; margin:0pt"><span style="font-family:Calibri; font-size:10pt">BIRD SM, Merrall ELC, Ward H, Will RG. </span><span style="font-family:Calibri; font-size:10pt">Survival and neurological re-operation rates after neurosurgical procedures in Scotland: implications for targeted surveillance of sub-clinical vCJD. </span></p><p style="line-height:13pt; margin:0pt"><span style="font-family:Calibri; font-size:10pt; font-style:italic">Neuroepidemiology</span><span style="font-family:Calibri; font-size:10pt"> 2009; 33: 1 - 11. (Also </span><span style="font-family:Calibri; font-size:10pt">DOI: 10.1159/000209281).</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 10pt 49.51pt; padding-left:4.49pt; text-align:center; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">BLOOD, TISSUE &amp; ORGAN SCREENING</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">SUMMARY</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Relatives’ refusal-rate in respect of brain-stem dead potential donors has increased from 30% in 1989-90 to 40% in the 21</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:Calibri; font-size:11pt"> century.  A </span><span style="font-family:Calibri; font-size:11pt">forteriori</span><span style="font-family:Calibri; font-size:11pt">, refusal  by relatives is the main barrier to cadaveric solid organ donation (please see notes: 27-33).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Only 1 500 deaths per annum (out of nearly 600 000 in UK: </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">CHECK</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> E&amp;W </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">vs</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> UK</span><span style="font-family:Calibri; font-size:11pt">) occur in such a manner that the deceased is a brain-stem dead potential donor (please see notes 34-38). </span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">England and Scotland, not just  Wales, should replace the NHS Organ Donor Register  (NHS ODR) with a much shorter, more manageable </span><span style="font-family:Calibri; font-size:11pt">register of those who opt-out</span><span style="font-family:Calibri; font-size:11pt"> from organ donation, or wish to register organ-specific opt-outs (please see notes 34-38; 40-44).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">There should be a presumption of consent for donation from brain-stem dead  potential donors who have not opted-out in life; and relatives should respect the presumption of consent by the deceased if s/he did not opt-out in life (please see note 39 &amp; 45 &amp; 47).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">If England and Wales do not replace NHS ODR and do not adopt presumed consent, then relatives should not have the right to over-rule the registered wishes of the deceased to donate all or specific organs (please see note 39).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Whether NHS ODR is to be replaced or not, prior to 2015 NHS ODR should be subject to a range of in-depth formal analyses on survivorship and look-up rates so that intelligence to aid the future design and conduct of opt-in or opt-out registers in the nations of the UK is gleaned (please see notes 42-44).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Performance measures for the detailed strategy of Taking Organ Transplantation to 2020 should be better differentiated, such as between brain-stem dead, cardiac death and living donors (please see notes 48-51).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">The strategy correctly states that UK will never have a world-class donation service if more than 4 out of every 10 families say no to donation.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 28.06pt; padding-left:7.94pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Carriage of Hepatitis C virus, obesity, and over-consumption of alcohol mean that UK has a growing need for liver transplantation.</span></li></ul><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><br style="page-break-before:always; clear:both" /></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">WRITTEN EVIDENCE</span><span style="font-family:Calibri; font-size:11pt"> on </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">TOPIC 1</span><span style="font-family:Calibri; font-size:11pt"> (Is NHS Blood and Transplant overly restrictive about who can donate) &amp; </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">TOPIC 4</span><span style="font-family:Calibri; font-size:11pt"> (changes that could be made safely to increase the supply of organs)</span></p><ol start="27" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">I conducted the 1989-90 confidential audit of all deaths in intensive care units in England and Wales which found that permission for solid organ donation was refused by 30% of families of brain-stem dead potential donors (557/1829). </span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">The 1989-90 confidential audit also showed that 95% of families of brain-stem dead potential donors were asked about organ donation: and so plans for “required request” legislation were set aside. Refusal by relatives, not failure to ask, was the major barrier.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">The 1989-90 confidential audit was designed to identify also organ-specific  barriers to donation, such as organ-specific refusal (corneas), organ-specific non-suitability (lungs), logistical failure to retrieve offered suitable organs (livers). Each was addressed: very soon thereafter liver retrievals were optimally efficient.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">During the 1989-90 audit, relatives’ refusal rate did decrease, but by a quarter only, during a brief period of sustained positive publicity about transplantation. Changing refusal rates is difficult.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">In the late 1980s, Gallup surveys of the UK public’s willingness to give consent for solid organ donation had also recorded consent-rates of around 70%, and so in accordance with the-then confidential audit .</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">In the early 21</span><span style="font-family:Calibri; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:Calibri; font-size:11pt"> century, a similar audit was re-instigated by NHS Blood and Transplant which discovered that relatives’ refusal rate had increased to 40% (1767/4445 in 2003-05 &amp; 2006-08 audits).</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Substantial increase in the UK in relatives’ refusal rate was thus well documented before the 2008 Organ Donor Taskforce reported. </span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Bird and Harris (2010) drew attention back to refusal by relatives as the key UK difficulty and documented the plausible gains in </span><span style="font-family:Calibri; font-size:11pt; font-style:italic">brain-stem dead donation</span><span style="font-family:Calibri; font-size:11pt"> were the UK not only to make, but to advocate, </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">the presumption of consent unless the deceased had, in life, opted-out</span><span style="font-family:Calibri; font-size:11pt"> from all cadaveric donation and or had registered organ-specific opt-outs. The approach to families is then: “in life, the deceased did not object – we presume that you also agree?”</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Bird and Harris (2010) reckoned that, with presumed consent, a </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">48%</span><span style="font-family:Calibri; font-size:11pt"> increase in the number of brain-stem dead donors from 6050 in 2000-2009 to 8930 was plausible </span><span style="font-family:Calibri; font-size:11pt">plausible</span><span style="font-family:Calibri; font-size:11pt"> based on assumed opt-out rate of 10% and 10% refusal by relatives of those who had not opted-out. A pessimistic scenario was also presented by which the 10-year increase was minimal, that is by </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">4%</span><span style="font-family:Calibri; font-size:11pt"> from 6050 to 6280 if the opt-out rate were 5% but relatives’ refusal rate remained at 40% in respect of potential donors who, in life, had not opted-out.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Whereas kidneys can be retrieved from cardiac-death donors, other solid organs from cadaveric donors (such as heart or liver) can only be retrieved after brain-stem death.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Annually, there are </span><span style="font-family:Calibri; font-size:11pt">only </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">around 1,500 brain-stem dead potential donors</span><span style="font-family:Calibri; font-size:11pt"> among all of UK’s 600,000 deaths:  that is, only 2.5 in 1,000 deaths</span><span style="font-family:Calibri; font-size:11pt"> occur in such a manner that cadaveric liver or heart donation is feasible.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">In practice, just over half of brain-stem dead potential donors become actual donors.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Framing by the 2008 Organ Donor Taskforce was wrong: instead of asking </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">why 10%</span><span style="font-family:Calibri; font-size:11pt"> of families of potential donors who had been registered on the NHS Organ Donor Register </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">had refused</span><span style="font-family:Calibri; font-size:11pt"> (and so overturned the wishes of the deceased), the Taskforce lauded a 90% re-affirmation rate.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">NHS Organ Donor Register (NHS ODR) was established in the mid 1990s, but minimally analysed. NHS ODR has registered barely 20 million persons despite 60%-willingness.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">I opposed NHS ODR from the outset: registration of millions when there are so few deaths per annum who are brain-stem dead potential donors makes less sense and is more error-prone than the registration of opt-outs who typically constitute 5% of a national population.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Analysis of NHS ODR should include how many registrations have been consulted/looked-up per annum and how many of the looked-up-persons have since died. A high associated death-rate is expected because look-up should primarily be to establish whether a person who may imminently be a potential cadaveric donor has registered his/her willingness for donation. Look-ups may be tens of 1000s per annum or as few as several 1000s only.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Indeed, the deceased should be culled from NHS ODR – whether look-up has occurred or not. Proper maintenance of NHS ODR is non-trivial, and may be a reason that many of the willing (such as I) do not sign-up.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Indeed, a computer-update at NHS Blood and Transplant has resulted in DVLA-registrants’ permissions for heart and corneal donation being interchanged on the NHS Organ Donor Register, a muddle that went undetected for nearly 10 years: until after the 2008 Organ Donor Taskforce had reported and when NHS Blood and Transplant began to write to new registrants to thank them and to confirm their permissions. Only by dint of the corrections received was the muddle discovered. Writing to half a million new opt-in registrants per annum is more costly than writing to all opt-out registrations would be.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">The number of UK brain-stem dead donors has not increased materially in the 5 years since the 2008 Organ Donor Taskforce reported, nor has relatives’ refusal rate decreased  in respect of brain-stem dead potential donors from around 40%.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Five years late but, nonetheless,  I very much welcome that the detailed Strategy for </span><span style="font-family:Calibri; font-size:11pt; font-style:italic">Taking Organ Transplantation to 2020</span><span style="font-family:Calibri; font-size:11pt"> now boldly and clearly states: “It must be clearly understood: the UK will never have a world-class donation and transplantation service if more than 4 out of every 10 families say no to donation”.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">I also welcome that the new strategy’s outcome measures make no mention of NHS ODR. The numbers ODR-registered are a distraction.  Instead, we need there to be a cultural presumption in favour of donation and public awareness that so few of us die in a manner as to enable brain-stem dead donation that this donor-rarity should be rarely denied.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Wales is too small a country from which to learn quickly the impact on consent-rate for brain-stem dead donation that the Welsh adoption of presumed consent makes.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">The new strategy (on page 7) refers to “consent/authorisation for organ donation” as an outcome measure. However, consent-rates for living organ donation, for brain-stem dead donation and for cardiac death donation are three distinct rates and should be addressed separately in terms of target-achievement.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Deceased organ donation is the second listed outcome measure. However, there is again a need to differentiate between brain-stem dead and cardiac-death donors; and also to recognise that cadaveric corneal donation is possible from many more deceased persons than is solid organ donation.</span></li><li style="font-family:Calibri; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">I welcome the focus on utilisation of specific organs but again caution that there are two distinct aspects: suitability of the specific organ for transplantation, and then the logistics of </span><span style="font-family:Calibri; font-size:11pt">explant</span><span style="font-family:Calibri; font-size:11pt">, transport and implantation of a priori suitable, consented donor organ.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">REFERENCES </span><span style="font-family:Calibri; font-size:11pt">on</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> TOPICS 1 </span><span style="font-family:Calibri; font-size:11pt">&amp;</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> 4</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Gore SM</span><span style="font-family:Calibri; font-size:10pt">, </span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Hinds</span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps"> CJ </span><span style="font-family:Calibri; font-size:10pt">and </span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Rutherford AJ</span><span style="font-family:Calibri; font-size:10pt">.  Organ donation from intensive care units in England.</span><span style="font-family:Calibri; font-size:10pt; font-style:italic"> British Medical Journal</span><span style="font-family:Calibri; font-size:10pt">  1989; </span><span style="font-family:Calibri; font-size:10pt; font-weight:bold">299</span><span style="font-family:Calibri; font-size:10pt">: 1193-1197.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Gilks</span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps"> WR</span><span style="font-family:Calibri; font-size:10pt">, </span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Gore SM</span><span style="font-family:Calibri; font-size:10pt"> and </span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Bradley BA</span><span style="font-family:Calibri; font-size:10pt">.  Predicting match grade and waiting-time to kidney transplantation.  </span><br /><span style="font-family:Calibri; font-size:10pt; font-style:italic">Transplantation</span><span style="font-family:Calibri; font-size:10pt">  1991; </span><span style="font-family:Calibri; font-size:10pt; font-weight:bold">51</span><span style="font-family:Calibri; font-size:10pt">: 618-624.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Gore SM</span><span style="font-family:Calibri; font-size:10pt">, </span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Taylor RMR </span><span style="font-family:Calibri; font-size:10pt">and </span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Wallwork</span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps"> J</span><span style="font-family:Calibri; font-size:10pt">.  Availability of transplantable organs from brain stem dead donors in intensive care units.  </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">British Medical Journal</span><span style="font-family:Calibri; font-size:10pt"> 1991; </span><span style="font-family:Calibri; font-size:10pt; font-weight:bold">302</span><span style="font-family:Calibri; font-size:10pt">: 149-153.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Gore SM</span><span style="font-family:Calibri; font-size:10pt">, </span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Cable DJ </span><span style="font-family:Calibri; font-size:10pt">and </span><span style="font-family:Calibri; font-size:10pt; font-variant:small-caps">Holland AJ</span><span style="font-family:Calibri; font-size:10pt">.  Organ donation from intensive care units in England and Wales: two year confidential audit of deaths in intensive care.  </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">British Medical Journal</span><span style="font-family:Calibri; font-size:10pt"> 1992; </span><span style="font-family:Calibri; font-size:10pt; font-weight:bold">304</span><span style="font-family:Calibri; font-size:10pt">: 349-355.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">Barber K, </span><span style="font-family:Calibri; font-size:10pt">Falvey</span><span style="font-family:Calibri; font-size:10pt"> S, Hamilton C, </span><span style="font-family:Calibri; font-size:10pt">Collett</span><span style="font-family:Calibri; font-size:10pt"> D, </span><span style="font-family:Calibri; font-size:10pt">Rudge</span><span style="font-family:Calibri; font-size:10pt"> C. Potential for organ donation in the United Kingdom: audit of intensive care records. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">British Medical Journal</span><span style="font-family:Calibri; font-size:10pt"> 2006; </span><span style="font-family:Calibri; font-size:10pt; font-weight:bold">332</span><span style="font-family:Calibri; font-size:10pt">: 1124-1127.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">BIRD SM. Please join the organ donor register: you could save a politician’s life. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Straight Statistics</span><span style="font-family:Calibri; font-size:10pt"> 2010; 25 October.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">BIRD SM, HARRIS J. Time to move to presumed consent for organ donation. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">British Medical Journal</span><span style="font-family:Calibri; font-size:10pt"> 2010; </span><span style="font-family:Calibri; font-size:10pt; font-weight:bold">340</span><span style="font-family:Calibri; font-size:10pt">:c2188.</span></p><p style="line-height:13pt; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">Royal Statistical Society Working Party on Performance Monitoring in the Public Services (SM Bird: chair)</span><span style="font-family:Calibri; font-size:10pt; font-style:italic">. Performance Indicators: Good, Bad, and Ugly. </span><span style="font-family:Calibri; font-size:10pt">London:  23 October 2003 (see Reports at www.rss.org.uk).</span></p><p style="line-height:13pt; margin:0pt"><span style="font-family:Calibri; font-size:10pt">Hutchinson SJ, BIRD SM, Goldberg DJ. Modelling the current and future disease burden of Hepatitis C among injecting drug users in Scotland. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Hepatology</span><span style="font-family:Calibri; font-size:10pt"> 2005; 42: 711 – 723.</span></p><p style="line-height:13pt; margin:0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:10pt">Hutchinson SJ, BIRD SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Clinical Gastroenterology and </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Hepatology</span><span style="font-family:Calibri; font-size:10pt"> 2005; 3: 1150-1159.</span></p><p style="line-height:13pt; margin:0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:10pt">McDonald SA, Hutchinson SJ, BIRD SM, Mills PR, Robertson C, Dillon J, Hayes P, Williams T, Goldberg DJ. Hospitalisation of hepatitis C diagnosed persons in Scotland for </span><span style="font-family:Calibri; font-size:10pt">decompensated</span><span style="font-family:Calibri; font-size:10pt"> cirrhosis: a population-based record linkage study. </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">European Journal of Gastroenterology and </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Hepatology</span><span style="font-family:Calibri; font-size:10pt"> 2010; 22: 49 - 57.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt; font-style:italic">January 2014</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 2.85pt 10pt 0pt"><span style="font-family:Calibri; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>